Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma

• A third ASCT may be an option for relapsed myeloma patients• If relapse ≥ 36 months after a tandem ASCT, median PFS was 24 months and OS 64 months• Toxicity after a third ASCT was acceptable• Progressive disease and Karnofsky score

http://www.bbmt.org/article/S1083-8791(18)30052-1/fulltext?rss=yes

Source: Biology of Blood and Marrow Transplantation - February 2, 2018 Category: Hematology Authors: Laurent Garderet, Simona Iacobelli, Linda Koster, Hartmut Goldschmidt, Jan-Erik Johansson, Jean Henri Bourhis, Marta Krejci, Xavier Leleu, Michael Potter, Didier Blaise, Christian Koenecke, Christian Peschel, Jakub Radocha, Bernd Metzner, Pascal Lenain, K Source Type: research